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Failures of breast conserving treatment in patients 
with early breast cancer
Zbigniew Jodkiewicz, Anna Skowroƒska-Gardas
A i m.  The aim of the study was to evaluate the rate and causes of failures of breast conserving treatment (BCT) in patients
with early breast cancer.
M a t e r i a l  a n d  m e t h o d s.  Between the years 1985 and 2002 in the 1st Department of Radiotherapy of the Maria
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology we have treated 571 patients with invasive breast cancer
in its early stage and 28 patients with preinvasive cancer. The duration of clinical symptoms of the disease before the
beginning of the treatment ranged between 0 (the tumor incidentally diagnosed by mammography or ultrasound) and 84
months. In 455 patients with invasive cancer and 23 with preinvasive cancer size of the tumor was less than 2 cm. In both
groups the most frequent localization was in the external quadrants. Within 3 – 12 weeks after breast conserving surgery external
beam irradiation with Co-60 or photons X 4-6 MeV to the total dose of 50 Gy in 25 fractions was performed. The irradiated
area covered the whole breast with an increased dose to the tumour site, predominantly with electrons 9-15 MeV in a dose of
10-15 Gy.
R e s u l t s.  Treatment failure in the form of local recurrence or distant metastases was observed in 48 patients (8%). Distant
metastases occurred in 37 women (6%), mainly in the lungs, the liver and the bones. Local recurrence was observed only in
9 patients (2%) with invasive cancer 12-80 months after completion of the treatment. In the group with preinvasive cancer we
observed local recurrence in 2 cases. At present there are still 547 patients alive from the group of 571 patients with invasive
cancer – 523 without relapse. 24 patients died during the first 5 – 115 months after the completion of treatment: 20 – due to
disease progression, 4 – due to other cancers. Total 5-year survival was 97%; disease free survival was 95.4%. The only factor
influencing survival was the presence of metastatic axillary lymph nodes.
C o n c l u s i o n s.  Breast conserving treatment is safe and well tolerated by patients with early breast cancer and provides a high
ratio of total and disease free survival. Failures are rare (8%) and are mostly caused by dissemination. Disseminated cancer
is significantly more frequent in patients with metastases in axillary lymph nodes (p<0.05). Local recurrence was observed only
in 2% of patients with invasive cancer, but occurred also in 2 patients with preinvasive tumors. Individually designed
conformal 3-D radiotherapy can reduce regional recurrence on the borders of the irradiated area.
Niepowodzenia po leczeniu oszcz´dzajàcym u kobiet chorych na raka piersi 
we wczesnych stopniach zaawansowania
C e l  p r a c y.  Celem pracy jest ustalenie cz´stoÊci i przyczyn wyst´powania niepowodzeƒ w leczeniu oszcz´dzajàcym (BCT)
chorych na wczesnego raka piersi.
M a t e r i a ∏  i m e t o d y.  W latach 1985-2002 w Zak∏adzie Teleradioterapii I Centrum Onkologii-Instytutu leczono 571
chorych na inwazyjnego raka piersi we wczesnych stopniach zaawansowania, oraz 28 chorych z rozpoznaniem raka
przedinwazyjnego. Czas trwania objawów waha∏ si´ od 0 (guz wykryty przypadkowo w badaniu mammograficznym lub
USG) do 84 miesi´cy. U 455 chorych na raka inwazyjnego i u 23 chorych na raka przedinwazyjnego wielkoÊç guza by∏a
mniejsza ni˝ 2 cm. W obu analizowanych grupach chorych nowotwór najcz´Êciej umiejscawia∏ si´ w kwadrantach
zewn´trznych. W okresie od 3 do 12 tygodni po oszcz´dzajàcym zabiegu chirurgicznym przeprowadzono leczenie prom. Co-60
lub fotonami X 4-6 MeV w dawce ca∏kowitej 50 Gy w 25 frakcjach na obszar ca∏ej piersi z podwy˝szeniem dawki
w przypadkach raka inwazyjnego na lo˝´ po guzie, przewa˝nie elektronami o energii 9-15 MeV w dawce 10-15 Gy.
W y n i k i.  Niepowodzenie leczenia w postaci nawrotu miejscowego lub przerzutów odleg∏ych obserwowano u 48 chorych, co
stanowi 8% ogólnej liczby leczonych. Przerzuty odleg∏e wystàpi∏y u 37 kobiet (6%), najcz´Êciej do p∏uc, wàtroby i koÊci.
Wznowa miejscowa wystàpi∏a jedynie u 9 (2%) chorych na raka inwazyjnego w okresie od 12 do 80 miesi´cy po zakoƒczeniu
1st Department of Radiotherapy
Maria Sk∏odowska-Curie Memorial Cancer Center
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Introduction
Breast conserving therapy (BCT) is now the basic
modality, and an alternative to mastectomy in the case of
early breast cancer in women. The results of randomized
studies published in the 1980’s and 1990’s, which were
aimed at comparing the survival of patients after BCT
and after mastectomy, have shown that, providing correct
patient qualification, the results of BCT are identical with
the results observed after mastectomy [1-9]. The results of
these studies have been compared in a double meta-
analysis performed by the Early Breast Cancer Trialists
Collaborative Group (EBCTCG) published in 1995 and
in 2000 [10, 11]. Despite the good treatment results of
BCT in some 5-10% of patients local recurrence is
observed during the first 5 years, and in another 5-10% of
patients – over the 10 years from the completion of
therapy [13, 13]. In such cases mastectomy remains the
treatment of choice. In 15-20% of patients distant
metastases appear – these are always an indication for
systemic therapy. The aim of this study is to attempt to
identify the frequency and causes of failure in patients
treated for breast cancer at our institution.
Material
Between the years 1985 and 2002 571 patients were treated for
invasive breast cancer in stage T1-2, N 0-1 and 28 patients were
treated for carcinoma ductale in situ (CDIS) at the 1st
Department of Teleradiotherapy of the Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology in Warsaw.
The age range of the patients was 23-75 years, mean age – 50 yrs.
The symptomatic history of the disease varied between 0
(tumour found accidentally in mammography or USG) to 84
months. In 366 patients from the invasive cancer group and in 24
patients with CDIS the symptomatic history did not exceed 1
month. In 455 patients from the invasive cancer group and in 23
patients with CDIS the size of the tumour was less than 2 cm. In
both the groups the most common localization of the tumour
was in the external quadrants of the breast (411 patients from
the invasive cancer group and 20 patients from the CDIS group).
Patient characteristics are presented in Table I.
Table I. Patient characteristics – women with early breast cancer
treated between 1985-2002
Invasive cancer Preinvasive cancer
Number of patients 571 28
Age
≤50 y. 291 12
>50 y. 280 16
Clinical staging
T1N0 451 –
T1N1 43 –
T2N0 59 –
T2N1 17 –
TXN1 1 –
TISN0 – 28
Pathology
ductal ca 326 –
lobular ca 91 –
others 154 –
dcis – 28
Metastatic lymph nodes
no 424 6
yes 128 –
Methods
All patients underwent BCT. In 534 patients from the invasive
cancer group tumorectomy (excision of the tumour with
a healthy tissue margin) was performed; 36 patients underwent
quadrantectomy, while in the case of 1 patient the primary lesion
was not found, while the excised mass turned out to be
a metastatic lymph node.
27 patients from the CDIS group underwent tumorectomy,
while only 1 patient had quadrantectomy. Axillary lympha-
denectomy was performed in 522 patients from the invasive
cancer group and in 6 patients with CDIS. 19 patients from the
invasive cancer group did not undergo lymphadenectomy,
because the primary lesion was less than 5 mm in diameter
(T1a). The most common histopathological form of cancer was
ductal carcinoma (326 patients). Lobular carcinoma was found in
91 patients. Metastases to the axillary nodes were found in 128
cases (23%). From 3 to 12 weeks after the surgical procedure the
patients underwent radiotherapy of the whole breast (Co-60 or
photons X 4-6 MeV) to a total dose of 50 Gy, with a boost to the
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leczenia. W grupie pacjentek leczonych z powodu raka przedinwazyjnego niepowodzenie z powodu nawrotu miejscowego
stwierdzono w 2 przypadkach. W chwili obecnej spoÊród 571 chorych na raka inwazyjnego, ˝yje 547, w tym 523 bez nawrotu
choroby. 24 chore zmar∏y w okresie od 5 do 115 miesi´cy po ukoƒczeniu leczenia. U 20 zgon by∏ wynikiem rozsiewu procesu
nowotworowego. Cztery chore zmar∏y z powodu innych nowotworów. Ca∏kowite prze˝ycie 5-letnie w omawianej grupie
wynios∏o 97%, a prze˝ycie bezobjawowe 95,4%. Jedynym czynnikiem, który mia∏ wp∏yw na rokowanie, by∏a obecnoÊç
przerzutów w w´z∏ach ch∏onnych do∏u pachowego.
W n i o s k i.  Leczenie oszcz´dzajàce stosowane w naszym oÊrodku jest bezpiecznà i dobrze tolerowanà metodà post´powania
u kobiet chorych na wczesnego raka piersi i pozwala osiàgnàç wysoki odsetek prze˝yç ca∏kowitych i bezobjawowych.
Niepowodzenia po leczeniu oszcz´dzajàcym wyst´pujà rzadko (w naszym materiale u 8% chorych) i sà przewa˝nie zwiàzane
z rozsiewem choroby. Rozsiew choroby stwierdza si´ znamiennie cz´Êciej u chorych z zaj´ciem w´z∏ów ch∏onnych do∏u
pachowego (p<0,05). Nawrót miejscowy by∏ obserwowany jedynie u 2% pacjentek z rozpoznanym rakiem inwazyjnym, ale
pojawi∏ si´ tak˝e u 2 chorych na raka przedinwazyjnego. Indywidualnie planowana radioterapia konformalna 3-D mo˝e
wp∏ynàç na ograniczenie nawrotów regionalnych, wyst´pujàcych na granicy pola napromienianego.
Key words: BCT, pattern of failures
S∏owa kluczowe: leczenie oszcz´dzajàce, niepowodzenia
tumour site in case of invasive carcinoma (usually with a 9-15
MeV electron beam). 64 patients also underwent irradiation of
the local nodal fields due to the presence of nodal metastases.
150 patients were administered chemotherapy acc. to the CMF
or AC protocol and 103 patients were administered hormono-
therapy due to the identification of poor prognostic factors
(tumour size exceeding 2 cm, high grade of histological
malignancy, the presence of metastases in the axillary nodes).
The treatment methods are presented in Table II.
Table II. Methods of treatment of patients with early breast cancer
treated between 1985-2002
Invasive Preinvasive 
cancer cancer
Surgery
Lumpectomy or quadrantectomy
yes 570 28
no 1 –
Axillary lymphadenectomy
yes 552 6
no 19 22
Radiotherapy
Whole breast: Co60, Phot X 4-6 mev,
total dose 50/Gy in 25 fractions
yes 571 28
no _ –
Boost: electrons 9-15 mev, Co60, Ir-192, 
total dose 10-15Gy/ 1-6 fractions
yes 559 –
no 12 28
Chemotherapy
yes 150 –
no 421 –
Hormonal therapy
yes 103 –
no 468 –
In order to compare the treatment results we have used the
Kaplan-Meier curve. Overall survival (OS) was defined as the
time between the onset of radiotherapy and the date of the final
follow-up, while disease-free survival (DFS) was defined as the
time until the diagnosis of local or distant failure. The
differences between the curves were analyzed with the log-rank
test; the level of statistical significance was set at p<0.05.
Results
Treatment tolerance was good; only in 48 pts. (8%) did we
have to postpone treatment for more than 7 days due to
leukopenia or post-irradiative reactions. In 356 patients
(94%) the cosmetic effect was estimated as very good or
good. At present 547/571 women with invasive cancer are
alive; of these 523 patients are disease-free. 24 patients
died between 5 and 115 months after the termination of
treatment – in 20 cases the cause of death was disease
dissemination. Four patients died due to another
malignancy – lung cancer, cancer of the oropharynx,
ovarian cancer and malignant astrocytoma. Mean OS of
the deceased patients was 47 months, median – 35
months. Treatment failure, both local or distant, was
observed in 46 patients (8%). Distant metastases were
observed in 37 women (6%) (median – 37.5 months),
mainly to the lungs, the liver and bones. Local failure
was observed only in 9 patients (2%) with invasive cancer
– between 12 and 80 months after treatment completion
(median 25 months). In 6 patients local failure was
observed during the first three years, in another 3 patients
– five years or more after treatment completion. In 7
patients the localization was directly in the site of the
primary tumour, only in 2 cases did it appear away from
the site of the primary tumour. In 6 cases salvage
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Figure 1. Survival without distant metastases in relation to the
presence of metastatic axillary lymph nodes
Group 1 = pN0 (447)
Group 2 = pN1 (124)
Figure 2. Survival without distant metastases in relation to the number
of metastatic axillary lymph nodes
Group 1 0 lymph nodes involved (447)
Group 2 1-3 lymph nodes involved (98)
Group 3 >3 lymph nodes involved (26)
mastectomy was performed – 2 of these patients develo-
ped distant metastases and eventually died. In the CDIS
group local failure was observed in 2 cases. In 1 of these
patients the site was identical with the primary tumour
site, in the other the local failure site was located at the
verge of the irradiated filed. In both of these women
these recurrence sites were invasive. They appeared 18
and 79 months after the termination of radiotherapy.
During the follow-up period 8 women developed cancer
of the contralateral breast – 7 of them underwent BCT
and 1 – mastectomy. All of these patients are alive; only 1
of them had developed metastases to the lungs and to
the brain, which were treated surgically and with radio-
chemotherapy and are have undergone complete re-
gression. This patient remains in follow-up. The OS in
this group was 97%, while DFS – 95.4%. The sole factor
found to influence OS and DFS was the presence of
metastases in the axillary nodes. Patients with metastases
to the axillary nodes had a significantly poorer prognosis
(p<0.05) as compared to patients without nodal meta-
stases (see survival curves 1, 2, 3). Patient age, hormonal
status, the size of the tumour and its histopathology did
not influence survival. The treatment results have been
collected and presented in Table III.
Table III. Results of treatment of patients
with early breast cancer treated between 1985- 2002
Invasive cancer Preinvasive cancer
Number of patients 571 28
Alive 547 28
No relapse 523 26
Local recurrence 7 2
Distant metastases 19 –
Independent cancer 11 –
Death 24 –
Local recurrence 2 –
Distant metastases 20 –
Independent cancer 4 –
Total 5-years survival 97% –
Disease free 5-years survival 95,4% -
Discussion
The modern approach to the treatment of women with
early breast cancer should be based on the following
outlines:
– highest probability of cure
– minimal risk of local and distant failure
– good cosmetic effect
– maximal amount of data concerning the type,
malignancy grade and advancement of the tumour
which will allow to choose the most appropriate option
of adjuvant therapy
BCT supported by radiation therapy allows achieving
all the listed goals. An analysis of randomized studies,
which had compared BCT with mastectomy has shown,
that the two treatment modalities do not differ signi-
ficantly as to the risk of local recurrence which was 5.9%
and 6.2%, respectively. In our material local failure was
observed only in 2% of patients, which is probably the
effect of a shorter follow-up period. Among the risk
factors influencing local failure one should list the
following: the extent of surgical excision (an important
element is the histopathological analysis of the final
resection margins), the presence of effuse intraductal
component (EIC) adjacent to the primary tumour, emboli
in the lymphatic vessels and the blood vessels around the
tumour, the type and extent of irradiation, the necessity
for systemic therapy and young patient age. From the
point of view of surgical treatment the most important
factor is the healthy tissue margin around the primary
tumour. If quadrantectomy or wide tumorectomy with
a margin of approx. 1.5-2 cm is performed the local
recurrence risk does not exceed 2% during the first 5
years [14, 15]. Veronesi and Fisher et al. have published
and compared the results of 20 years of follow-up after
BCT and mastectomy in patients with early breast cancer.
These results were practically identical and the local
recurrence risk was 8.8% and 14.3%, respectively [16,
17]. However, if the healthy tissue margin is narrow or
there is no healthy tissue margin the risk of local
recurrence increases to 10-20%. The diagnosis of
recurrence is problematic as the infiltration is often
masked by post-irradiation fibrosis. High radiation doses
limit the local recurrence risk but they also render early
diagnosis of recurrence even more difficult, thus causing
the danger of recognizing recurrence in a very advanced,
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Figure 3. Survival without distant metastases in relation to the lymph
node index
Group 1 lymph nodes index 0% (447)
Group 2 lymph nodes index 1-30% (105)
Group 3 lymph nodes index >30% (19)
untreatable stage. In some 1/3 of the recurring patients
the lesion may only be discerned mammographically, in
another 1/3 it is discernible clinically, while in the
remaining 1/3 the diagnosis may be both clinical and
mammographic. Local recurrences are usually found
within the primary tumour site. If the recurrence is
located in a different quadrant it should not be recognized
as a recurrence, but rather as another primary carcinoma
of the breast. Veronesi et al. in a group of 2233 patients
with breast cancer observed 119 cases of local recurrence,
50% of which were located in the direct vicinity of the
primary tumour site while the remaining 50% were
located in a different quadrant [18]. This data is contrary
to the findings of Fowble and Kurtz, who, in their study
groups, had observed a majority of local recurrences (65%
and 79%, respectively) directly within the primary tumour
site [19, 20]. In our material recurrence was observed in
11 cases – in 9 within the primary tumour site and in 2 in
a different localization. Isolated recurrences within the
breast tissue may be treated with mastectomy, after which
the 5-year survival ratio reaches 50-84% [19, 21, 22]. The
recent years have brought a period of interest in the
biological factors and in their influence on the clinical
course of breast cancer. Voogd et al. have performed
a controlled trial in an attempt to verify which histological
factors are connected with an increased risk of recurrence
after BCT. They found that the recurrence risk increases
significantly in the presence of effuse intraductal
component (EIC) adjacent to the primary tumour and
in the presence of intravascular emboli [23]. This opinion
is supported by Veronesi, who has observed a twofold
higher risk of local recurrence in patients with EIC [18].
In our institution in all the cases where EIC is found on
histopathological examination we perform a radical
mastectomy. Another factor potentially influencing
prognosis is the grade of histological malignancy (G).
Kurtz et al. have performed an analysis of 1593 patients
and have observed 181 cases of local recurrence; of these
patients 159 underwent mastectomy and the main
prognostic factor (apart from DFS and the size of the
recurrent tumour) was the grade of histological
malignancy (G). Patients with a low G value (1-2) had
a significantly better prognosis (72% of 5-year survivals)
than patients with a high G value (40% of 5-year
survivals) [20]. According to some authors younger
patient age (below 40 yrs.) may also have a negative
impact on survival. This is probably caused by the
presence of less mature forms of the cancer and the
multifocal character of the lesions [24]. In our material we
found no impact of patient age upon prognosis.
Radiotherapy is a very important factor in the curative
process, disregarding the kind of surgical technique
applied, as has been proven in a vast number of
publications. The risk of local recurrence is 5-7 times
lesser in irradiated patients as compared to patients
treated with surgery only, although the direct influence of
radiotherapy on survival has not yet been proven [25, 26,
27]. In our material all the patients underwent whole
breast irradiation and only in 12 cases did we refrain from
a boost to the tumour site due to the very small size of the
primary lesion (i.e. below 5 mm – T1a). We applied
a technique of two opposite, oblique fields in 2D system,
which probably explains the appearance of two local
recurrences at the border of the two irradiated fields. In
order to avoid such complications since the end of the
year 2003 we use individually planned conformal 3D
radiotherapy in all our patients.
Among the prognostic factors directly influencing
dissemination the most important one is the presence of
metastases in the axillary nodes. We observed significantly
shorter survivals in patients with metastases to the axillary
nodes as compared to patients without axillary metastases.
Similar reports have been reported in literature [7, 16-18].
Conclusions
1. At our institution BCT is a safe and well tolerated
treatment modality in patients with early breast cancer.
It allows achieving a high ratio of OS and DFS (97%
and 95.5%, respectively).
2. Failures after BCT are rare (8%) and are usually
caused by disease dissemination.
3. Generalized disease is significantly more common in
patients with metastases to the axillary nodes (p<0.05).
4. Local failure has been observed in only 2% of patients
with recognized invasive cancer but we have also noted
two cases of local failure in patients with DCIS.
5. Individually planned conformal 3D radiotherapy may,
in the near future, cause a further decrease in the ratio
of locoregional failures.
Zbigniew Jodkiewicz MD, PhD
1st Department of Radiotherapy
Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology
Wawelska 15, 00-973 Warsaw, Poland
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